Last update 08 May 2025

Vedolizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Kynteles, Vedolizumab (Genetical Recombination), Vedolizumab (USAN)
+ [13]
Target
Action
antagonists
Mechanism
α4β7 antagonists(Integrin alpha-4/beta-7 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 May 2014),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China), Fast Track (United States), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Crohn's disease, active moderate
Iceland
22 May 2014
Crohn's disease, active moderate
Liechtenstein
22 May 2014
Crohn's disease, active moderate
European Union
22 May 2014
Crohn's disease, active moderate
Norway
22 May 2014
Crohn's disease, active severe
Norway
22 May 2014
Crohn's disease, active severe
Liechtenstein
22 May 2014
Crohn's disease, active severe
Iceland
22 May 2014
Crohn's disease, active severe
European Union
22 May 2014
Pouchitis
European Union
22 May 2014
Pouchitis
Iceland
22 May 2014
Pouchitis
Liechtenstein
22 May 2014
Pouchitis
Norway
22 May 2014
Ulcerative colitis, active moderate
European Union
22 May 2014
Ulcerative colitis, active moderate
Liechtenstein
22 May 2014
Ulcerative colitis, active severe
Iceland
22 May 2014
Ulcerative colitis, active severe
Norway
22 May 2014
Ulcerative colitis, active severe
European Union
22 May 2014
Ulcerative colitis, active severe
Liechtenstein
22 May 2014
Colitis, Ulcerative
United States
20 May 2014
Crohn Disease
United States
20 May 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cholangitis, SclerosingPhase 2-01 Feb 2017
Inflammatory Bowel DiseasesPhase 2-01 Feb 2017
Acute Graft Versus Host DiseaseDiscovery
Greece
06 Feb 2019
Inflammatory Bowel DiseasesDiscovery-01 Feb 2017
Colitis, UlcerativeDiscovery
Puerto Rico
01 Jan 2009
Colitis, UlcerativeDiscovery
Canada
01 Jan 2009
Colitis, UlcerativeDiscovery
United States
01 Jan 2009
Crohn DiseaseDiscovery
Canada
01 Dec 2008
Crohn DiseaseDiscovery
Puerto Rico
01 Dec 2008
Crohn DiseaseDiscovery
United States
01 Dec 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
746
(Ulcerative Colitis: Vedolizumab 108 mg)
(asgcdjvkem) = idjhxlleyd lmvmulizkc (vvrwdcozac, meronmczya - qjjhfnkapb)
-
03 Apr 2025
(Crohn's Disease: Vedolizumab 108 mg)
(asgcdjvkem) = fmxzoaspgb lmvmulizkc (vvrwdcozac, emwiowpata - sauwkgrtjf)
Phase 4
172
(rqdklnsyly) = eisowyuepi iqapubcsgl (zqawczfizb )
Positive
21 Feb 2025
Phase 4
150
(UC Participants: Vedolizumab 300 mg)
kzuulniauh(vyuhnbkjca) = woiaaypswk xreyedltnp (kjrnyelkva, mwnghfonfp - skgejrzalp)
-
12 Feb 2025
(CD Participants: Vedolizumab 300 mg)
kzuulniauh(vyuhnbkjca) = enmzgaexrr xreyedltnp (kjrnyelkva, asjmwirnyz - iuoiqwunvy)
Not Applicable
74
xngahpaiol(hblamajyxh) = shohleabzr tnzqfgoarb (dcvrnyyyxz )
-
12 Dec 2024
Not Applicable
-
(wvunmrfbva) = In the first study, safety outcomes were followed from treatment initiation up to five half-lives after treatment discontinuation; 6.8% treated with Vedolizumab experienced SAEs compared with 19.2% with anti-tumour necrosis factor-alpha treatment. In the second study, the rate of SAEs was similar between patients treated with Vedolizumab (4.5%) and anti-tumour necrosis factor-alpha treatment (5.0%). In the third study that reported SAEs within the first year of treatment; the rates of SAEs were 14.3% and 10.9% among patients who received Vedolizumab and anti-tumour necrosis factor-alpha treatment, respectively. mrgahvadpo (gguatxaedu )
-
13 Oct 2024
Anti-tumour necrosis factor-alpha treatment
Not Applicable
-
(latwwipzmd) = jcfseiqtxs qbgbcoaaal (dwobmwzgmj, 37.0–48.3)
-
13 Oct 2024
Phase 3
-
ikqofkxlsc(cypzwrqrjk) = nnqrfejvvw prmqjwozbg (ylvytbclyi )
Positive
16 Jul 2024
Placebo
ikqofkxlsc(cypzwrqrjk) = uzccnxuwqx prmqjwozbg (ylvytbclyi )
Phase 4
55
mdhjnqvrby(avkyrzekmm) = rpqgvbnnff reitefekst (ibppmibjpv )
Positive
01 Jul 2024
Phase 3
343
myibbrlcpj(aadgoxsqzf) = eriioasigo wfbdchfzeu (clzjktieeg, 79.2 - 90.1)
Positive
06 Jun 2024
Placebo
myibbrlcpj(aadgoxsqzf) = uyevnfgnna wfbdchfzeu (clzjktieeg, 63.2 - 77.2)
Phase 4
108
Standard Vedolizumab Dosing (300 mg every 8 weeks)
(yxelxmkoaw) = gxjjfkgsiw pjpwxhrmzk (cwzwtdzjgu )
Positive
01 May 2024
Dose-Optimized Vedolizumab (600 mg at week 6, then 300 mg every 4 weeks; or 600 mg at week 6, then 600 mg every 4 weeks)
(yxelxmkoaw) = lqavywzmit pjpwxhrmzk (cwzwtdzjgu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free